Viridian Therapeutics/$VRDN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Ticker
$VRDN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
143
ISIN
US92790C1045
Website
VRDN Metrics
BasicAdvanced
$1.2B
-
-$3.33
0.62
-
Price and volume
Market cap
$1.2B
Beta
0.62
52-week high
$25.21
52-week low
$9.90
Average daily volume
742K
Financial strength
Current ratio
19.487
Quick ratio
18.876
Long term debt to equity
3.734
Total debt to equity
3.822
Interest coverage (TTM)
-110.67%
Profitability
EBITDA (TTM)
-336.492
Gross margin (TTM)
-78,484.11%
Net profit margin (TTM)
-102,092.38%
Operating margin (TTM)
-111,590.73%
Management effectiveness
Return on assets (TTM)
-32.62%
Return on equity (TTM)
-51.95%
Valuation
Price to revenue (TTM)
3,515.342
Price to book
2.86
Price to tangible book (TTM)
2.86
Price to free cash flow (TTM)
-3.786
Free cash flow yield (TTM)
-26.41%
Free cash flow per share (TTM)
-384.31%
Growth
Revenue change (TTM)
4.86%
Earnings per share change (TTM)
15.17%
3-year revenue growth (CAGR)
-44.09%
3-year earnings per share growth (CAGR)
-13.43%
What the Analysts think about VRDN
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
Bulls say / Bears say
Viridian's lead candidate, veligrotug (VRDN-001), demonstrated strong efficacy in Phase 3 trials for both active and chronic Thyroid Eye Disease (TED), meeting all primary and secondary endpoints with high statistical significance, indicating potential for market approval and adoption. (panabee.com)
The company maintains a robust cash position of $753.2 million as of September 30, 2024, bolstered by successful public offerings, providing sufficient funds to support operations into the second half of 2027 without immediate need for additional financing. (businesswire.com)
Analyst consensus reflects optimism, with an average 12-month price target of $40.35, suggesting significant upside potential from current trading levels. (alphaspread.com)
Viridian reported a net loss of $270 million for FY 2024, an increase from $238 million in FY 2023, highlighting ongoing financial losses and dependence on external financing. (panabee.com)
The company observed hearing impairment adverse events in veligrotug-treated patients during THRIVE and THRIVE-2 trials, which may necessitate careful monitoring and could impact the drug's market acceptance. (panabee.com)
Viridian relies on a single contract development and manufacturing organization (CDMO), WuXi Biologics, for clinical material manufacturing, creating supply chain vulnerabilities, especially amid potential U.S. legislative actions targeting WuXi. (panabee.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
VRDN Financial Performance
Revenues and expenses
VRDN Earnings Performance
Company profitability
VRDN News
AllArticlesVideos
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Business Wire·4 weeks ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viridian Therapeutics stock?
Viridian Therapeutics (VRDN) has a market cap of $1.2B as of June 27, 2025.
What is the P/E ratio for Viridian Therapeutics stock?
The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of June 27, 2025.
Does Viridian Therapeutics stock pay dividends?
No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Viridian Therapeutics dividend payment date?
Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Viridian Therapeutics?
Viridian Therapeutics (VRDN) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.